SRAD vs GENI

For growth investors, Genius Sports Limited (GENI) is the stronger pick with 31.

0% revenue growth year-over-year, versus 12. 0% for Sportradar Group AG (SRAD). Sportradar Group AG (SRAD) offers the better valuation at 38. 7x trailing P/E (33. 1x forward), making it the more compelling value choice. Analysts rate Sportradar Group AG (SRAD) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sportradar Group AG is actually cheaper at 33.

1x.

Over the past 5 years, Sportradar Group AG (SRAD) delivered a total return of -45.

5%, compared to -74. 6% for Genius Sports Limited (GENI). Over 10 years, the gap is even starker: SRAD returned -45. 5% versus GENI's -52. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sportradar Group AG (SRAD) is the lower-risk stock at 0.

65β versus Genius Sports Limited's 1. 50β — meaning GENI is approximately 130% more volatile than SRAD relative to the S&P 500. On balance sheet safety, Genius Sports Limited (GENI) carries a lower debt/equity ratio of 4% versus 6% for Sportradar Group AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Genius Sports Limited (GENI) is pulling ahead at 31.

0% versus 12. 0% for Sportradar Group AG (SRAD). On earnings-per-share growth, the picture is similar: Sportradar Group AG grew EPS 200. 0% year-over-year, compared to -63. 0% for Genius Sports Limited. Over a 3-year CAGR, GENI leads at 25. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sportradar Group AG (SRAD) is the more profitable company, earning 7.

8% net margin versus -16. 7% for Genius Sports Limited — meaning it keeps 7. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRAD leads at 9. 1% versus -15. 6% for GENI. At the gross margin level — before operating expenses — GENI leads at 23. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sportradar Group AG (SRAD) trades at 33.

1x forward P/E versus 52. 4x for Genius Sports Limited — 19. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GENI: 153. 9% to $12. 10.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sportradar Group AG (SRAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65)). Genius Sports Limited (GENI) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRAD: -45. 5%, GENI: -52. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SRAD (Technology) and GENI (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SRAD is a small-cap quality compounder stock; GENI is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.